Phaseline

Targets › PARP3

PARP3 (Protein mono-ADP-ribosyltransferase PARP3): drug programs, companies and trials

9 programs from 9 companies in 217 trials: 102 Phase 2, 85 Phase 1, 24 Phase 3, 6 Phase 4; Oncology, Other, Genitourinary; next expected readout Nov 2026.

Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins and plays a key role in the response to DNA damage. Mediates mono-ADP-ribosylation of glutamate, aspartate or lysine residues on target proteins. (UniProt, Q9Y6F1)

Open in Phaseline: the race on PARP3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaOlaparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 4Metastatic Castration-resistant Prostate Cancer; Advanced Ovarian Cancer; Platinum Sensitive; Endometrial Neoplasms …Nov 2026
M.D. Anderson Cancer Center[18F]-4FN
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274Phase 4Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm …Dec 2026
Alliance for Clinical Trials in OncologyRucaparib camsylate
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 3Castration-Resistant Prostate CarcinomaMar 2027
The Netherlands Cancer InstituteddAC-CP-Olaparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP2, PARP3Phase 3Breast Cancer; Cancer; Ovarian CancerMay 2027
Merck & Co. (MSD)Olaparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 3Lung Neoplasms; Small Cell Lung Cancer; Solid Tumors; Advanced Solid Neoplasms …May 2027
pharmaandRucaparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 3Epithelial Ovarian Cancer; Leiomyosarcoma; Peritoneal Cancer; Adenocarcinoma of the Oesophagus …Dec 2030
National Cancer Institute (NCI)Veliparib
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 2Acute Myeloid Leukemia; Glioblastoma; Locally Advanced Pancreatic Adenocarcinoma; Recurrent Lung Small Cell Carcinoma …Nov 2026
Daewoong PharmaceuticalOlaparib (DWZ2501)
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 1CancerMar 2027
Boryung PharmaceuticalOlaparib (BR2022)
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 1Ovarian Cancer–

Conditions

Ovarian Cancer (11) Breast Cancer (9) Acute Myeloid Leukemia (8) Advanced Malignant Solid Neoplasm (7) Prostate Cancer (6) Metastatic Castration-resistant Prostate Cancer (4) Solid Tumor (4) Glioma (3) Metastatic Malignant Solid Neoplasm (3) Lung Cancer (3) Cancer (3) Solid Tumors (2)

Modalities

small molecule (6), mixed (3)

Companies

AstraZeneca (1) Merck & Co. (MSD) (1) National Cancer Institute (NCI) (1) pharmaand (1) The Netherlands Cancer Institute (1) Alliance for Clinical Trials in Oncology (1) Boryung Pharmaceutical (1) M.D. Anderson Cancer Center (1) Daewoong Pharmaceutical (1)

Related targets

PARP1 (9) PARP2 (9) CHRNB2 (1) CHRNA4 (1) Tubulin (1) OPRM1 (1) CD274 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.